news
Self-assembling nanofibres could prevent damage from inflammation
A team has demonstrated in mouse models that a self-assembling nanofibre material could limit the damage caused by cytokines in inflammatory diseases.
List view / Grid view
Antibodies
webinar
Imaging Mass Cytometry™ of malignant tissue architecture: rare single cells to structured multi-cellular communities
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
webinar
Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
whitepaper
Article: Defeating COVID-19: The science behind a new ELISA
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
whitepaper
Article: Multisystem inflammatory syndrome in children with COVID-19
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
article
Fighting HIV: could antibodies be the answer?
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
article
The development of biomaterial-based vaccine platforms against viruses
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
article
Broad T-cell responses: designing a rhinovirus vaccine
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
whitepaper
Product hub: Presenting the Fluidity One-W Serum
Don’t miss the latest product hub from Fluidic Analytics, detailing the Fluidity One-W Serum which enables comprehensive profiling of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a crucial characteristic of protein interactions that traditional tests cannot easily quantify.
whitepaper
Product hub: A cost, time and labour-saving protein purification platform
In February 2021, US biotech company GenScript launched an updated version of its semi-automated system, AmMag™ SA Plus.
news
Antibody could be used in tooth regeneration therapy, study shows
A mAb could be used in tooth regeneration therapy, after a single administration generated new teeth in mice and ferrets.
news
Antibodies and remdesivir used to treat Marburg virus in rhesus macaques
The combination of mAbs and remdesivir induced an 80 percent protection rate against Marburg virus in rhesus macaques, according to a new study.
article
Drug Target Review – Issue 1 2021
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
